Overview

Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Patients will be randomized the day of surgery upon presentation to the operating room to either a treatment group (PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine) or a control group (PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline) using secure web-based randomization. Assignments will be based on computer-generated code. Clinicians will not be blinded to the intervention, but all outcomes will be assessed by research personnel who are blinded to the group assignment.
Phase:
Early Phase 1
Details
Lead Sponsor:
The Cleveland Clinic
Treatments:
Bupivacaine